Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway.

Laprevotte E, Cochaud S, du Manoir S, Lapierre M, Dejou C, Philippe M, Giustiniani J, Frewer KA, Sanders AJ, Jiang WG, Michaud HA, Colombo PE, Bensussan A, Alberici G, Bastid J, Eliaou JF, Bonnefoy N.

Oncotarget. 2017 Dec 6;8(69):113360-113372. doi: 10.18632/oncotarget.23008. eCollection 2017 Dec 26.

2.

CD39: A complementary target to immune checkpoints to counteract tumor-mediated immunosuppression.

Bonnefoy N, Bastid J, Alberici G, Bensussan A, Eliaou JF.

Oncoimmunology. 2015 Feb 3;4(5):e1003015. eCollection 2015 May.

3.

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells.

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E, Alberici G, Bonnefoy N, Eliaou JF, Bastid J, Bensussan A, Giustiniani J.

Sci Rep. 2015 Jul 8;5:11874. doi: 10.1038/srep11874.

4.

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity.

Bastid J, Regairaz A, Bonnefoy N, Déjou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, Gros L, Bec N, Larroque C, Alberici G, Bensussan A, Eliaou JF.

Cancer Immunol Res. 2015 Mar;3(3):254-65. doi: 10.1158/2326-6066.CIR-14-0018. Epub 2014 Nov 17.

5.

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.

Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A, Bastid J.

Sci Rep. 2013 Dec 9;3:3456. doi: 10.1038/srep03456.

6.

ENTPD1/CD39 is a promising therapeutic target in oncology.

Bastid J, Cottalorda-Regairaz A, Alberici G, Bonnefoy N, Eliaou JF, Bensussan A.

Oncogene. 2013 Apr 4;32(14):1743-51. doi: 10.1038/onc.2012.269. Epub 2012 Jul 2. Review.

PMID:
22751118
7.

Mice Drawer System: phase c/d development and perspective.

Cancedda R, Pignataro S, Alberici G, Tenconi C.

J Gravit Physiol. 2002 Jul;9(1):P337-8.

PMID:
15002603
8.
9.

Evidence for an involvement of the neutrophil integrin lymphocyte function-associated antigen-1 in early failure of heart transplants.

Oubenaissa A, Mouas C, Bourgeois F, Le Deist F, Albérici G, Moalic JM, Menasché P.

Circulation. 1996 Nov 1;94(9 Suppl):II254-9.

PMID:
8901756
10.

A dose-searching trial of an anti-LFA1 monoclonal antibody in first kidney transplant recipients.

Le Mauff B, Le Meur Y, Hourmant M, Debray M, Boeffard F, Alberici G, Soulillou JP, Scherrmann JM.

Kidney Int Suppl. 1996 Jan;53:S44-50.

PMID:
8770990
11.

Evaluation of a new preservation solution: Celsior in the isolated rat lung. Paris-Sud University Lung Transplatation Group.

Reignier J, Mazmanian M, Chapelier A, Alberici G, Ménasché P, Weiss M, Hervé P.

J Heart Lung Transplant. 1995 May-Jun;14(3):601-4.

PMID:
7654745
12.

Anti-LFA-1 adhesion molecule monoclonal antibody in prophylaxis of human kidney allograft rejection.

Le Mauff B, Hourmant M, Le Meur Y, Dantal J, Cantarovich D, Caudrelier P, Alberici G, Soulillou JP.

Transplant Proc. 1995 Feb;27(1):865-6. No abstract available.

PMID:
7879210
13.

Treatment of acute rejection in renal graft recipients by thymoglobuline: a retrospective multicenter analysis.

Bock P, Hobler N, Caudrelier P, Alberici G.

Transplant Proc. 1995 Feb;27(1):1058-9. No abstract available.

PMID:
7878802
14.

Direct assessment of the antioxidant effects of a new heart preservation solution, Celsior. A hemodynamic and electron spin resonance study.

Pietri S, Culcasi M, Albat B, Albérici G, Menasché P.

Transplantation. 1994 Sep 27;58(6):739-42. No abstract available.

PMID:
7940702
15.

Experimental evaluation of Celsior, a new heart preservation solution.

Menasché P, Termignon JL, Pradier F, Grousset C, Mouas C, Alberici G, Weiss M, Piwnica A, Bloch G.

Eur J Cardiothorac Surg. 1994;8(4):207-13.

PMID:
8031565
16.

Efficacy of lactobionate-enriched cardioplegic solution in preserving compliance of cold-stored heart transplants.

Menasché P, Hricak B, Pradier F, Cheav SL, Grousset C, Mouas C, Albérici G, Bloch G, Piwnica A.

J Heart Lung Transplant. 1993 Nov-Dec;12(6 Pt 1):1053-61.

PMID:
8312306
17.

Biochemical, behavioral, and electrophysiologic actions of the selective sigma receptor ligand (+)-pentazocine.

Steinfels GF, Alberici GP, Tam SW, Cook L.

Neuropsychopharmacology. 1988 Dec;1(4):321-7.

PMID:
2855202
18.

Conjugates of elliptinium acetate with mouse monoclonal anti-alpha-fetoprotein antibodies or Fab fragments: in vitro cytotoxic effects upon human hepatoma cell lines.

Alberici GF, Pallardy M, Manil L, Dessaux JJ, Fournier J, Mondesir JM, Bohuon C, Gros P.

Int J Cancer. 1988 Feb 15;41(2):309-14.

PMID:
2448254
19.

Development of a computerized system for inventory of controlled drug substances.

Schmidt W, Alberici G, Cook L.

NIDA Res Monogr. 1988;81:163-6.

PMID:
3136356
20.

Antibody recognition of substituted ammonium ions. Modulation by the counterion.

Pallardy M, Alberici GF, Goodman A, Bohuon C.

J Immunol Methods. 1987 May 20;99(2):179-83.

PMID:
3584990

Supplemental Content

Loading ...
Support Center